A medicament comprising at least one furoxan NO donor of formula: wherein R 1 and R 2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 0-6 alkylCO 2 R 3, -C 0-6 alkylC R 3, -C 0-6 alkylC NHR 4, -C 0-6 alkylN(R 4) 2, -C 0-6 alkylN + (R 7) 3, -C 0-6 alkylOR 5, -C 0-6 alkylSR 5, -C 0-6 alkylC(=NR 6)R 3, -C 0-6 alkylN=NR 5, -C 0-6 alkylNR 4 N(R 4,) 2, -C 0-6 alkylNR 4 C(=NR 4)N(R 4,) 2, -C 0-6 alkylhalo, -C 0-6 alkylS R 3, -C 0-6 alkylSO 2 R 3, -CN and -NO 2; or R 1 and R 2 taken together with the carbon atoms to which they are attached form an optionally substituted 5 to 8 membered saturated or unsaturated carbocyclic or heterocyclic ring, an aryl ring or a heteroaryl ring; R 3 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 1-6 alkylCO 2 R 7, -C 0-6 alkylN(R 4) 2, -C 1-6 alkylNR 4 C(=NR 4)N(R 4,) 2 -C 1-6 alkylOR 7 and -C 1-6 alkylSR 7; each R 4 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 0-6 alkylC R 8, -C 0-6 alkylC R 8, -C 0-6 alkylCO 2 R 7, -C 0-6 alkylSO 2 R 8 and -C 0-6 alkylOR 7; R 5 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 0-6 alkylC R 7, -C 0-6 alkylCO 2 R 8, -C 0-6 alkylN(R 7) 2, -C 0-6 alkylC N(R 7) 2, -C 1-6 alkylOR 7 and -C 1-6 alkylSR 7; R 6 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 0 6 alkylNHC N(R 7) 2, -C 0-6 alkyNHC R 7, -C 0-6 alkylNHSO 2 R 7, -C 0-6 alkylNHCO 2 R 7, -C 0-6 alkylOC R 7, -C 0-6 alkylC R 7, -CN and -OR 7; each R 7 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl and -C 0-6 alkylheteroaryl; and R 8 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl and -N(R 7) 2; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl and heteroaryl group is optionally substituted; or a pharmaceutically compatible salt thereof; for use in treating or preventing a neuropathic condition in a subject, wherein the furoxan NO donor is for administration at a level that enhances NO and that does not alter normal systemic vascular tone in the subject. wherein R 1 and R 2 are independently selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 0-6 alkylCO 2 R 3, -C 0-6 alkylC R 3, -C 0-6 alkylC NHR 4, -C 0-6 alkylN(R 4) 2, -C 0-6 alkylN + (R 7) 3, -C 0-6 alkylOR 5, -C 0-6 alkylSR 5, -C 0-6 alkylC(=NR 6)R 3, -C 0-6 alkylN=NR 5, -C 0-6 alkylNR 4 N(R 4,) 2, -C 0-6 alkylNR 4 C(=NR 4)N(R 4,) 2, -C 0-6 alkylhalo, -C 0-6 alkylS R 3, -C 0-6 alkylSO 2 R 3, -CN and -NO 2; or R 1 and R 2 taken together with the carbon atoms to which they are attached form an optionally substituted 5 to 8 membered saturated or unsaturated carbocyclic or heterocyclic ring, an aryl ring or a heteroaryl ring; R 3 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 1-6 alkylCO 2 R 7, -C 0-6 alkylN(R 4) 2, -C 1-6 alkylNR 4 C(=NR 4)N(R 4,) 2 -C 1-6 alkylOR 7 and -C 1-6 alkylSR 7; each R 4 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 0-6 alkylC R 8, -C 0-6 alkylC R 8, -C 0-6 alkylCO 2 R 7, -C 0-6 alkylSO 2 R 8 and -C 0-6 alkylOR 7; R 5 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 0-6 alkylC R 7, -C 0-6 alkylCO 2 R 8, -C 0-6 alkylN(R 7) 2, -C 0-6 alkylC N(R 7) 2, -C 1-6 alkylOR 7 and -C 1-6 alkylSR 7; R 6 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl, -C 0 6 alkylNHC N(R 7) 2, -C 0-6 alkyNHC R 7, -C 0-6 alkylNHSO 2 R 7, -C 0-6 alkylNHCO 2 R 7, -C 0-6 alkylOC R 7, -C 0-6 alkylC R 7, -CN and -OR 7; each R 7 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl and -C 0-6 alkylheteroaryl; and R 8 is selected from hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, -C 0-6 alkylcycloalkyl, -C 0-6 alkylcycloalkenyl, -C 0-6 alkylaryl, -C 0-6 alkylheterocyclyl, -C 0-6 alkylheteroaryl and -N(R 7) 2; wherein each alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl and heteroaryl group is optionally substituted; or a pharmaceutically compatible salt thereof; for use in treating or preventing a neuropathic condition in a subject, wherein the furoxan NO donor is for administration at a level that enhances NO and that does not alter normal systemic vascular tone in the subject.